The American restaurant industry is facing an unexpected challenge: GLP-1 weight loss drugs are not just changing consumers’ bodies, they are changing their eating habits too.
The impact is showing up at the register, as more and more customers are cutting back on dining out, ordering smaller quantities, and even avoiding alcohol. Major fast food and casual dining chains across the United States are watching this new reality with growing unease, trying to figure out whether this is a passing trend or a deep, lasting shift in consumer behavior.
Customers Are Eating Less, and Differently
Natalie Green, a fertility nurse in Manhattan, recalls how she used to travel all the way to Jersey City just to enjoy the famous oversized portions at the Cheesecake Factory. But since she started treatment with Zepbound two years ago, her relationship with food has changed entirely.
As she told the Wall Street Journal, she now gravitates toward lighter options like Chipotle meals, which she finds fresher and more balanced. The enormous portions that were once a hallmark of American food culture no longer hold any appeal for her.
Kaye Kohlmann, a nurse from Wisconsin, tells a similar story. Before she and her husband began GLP-1 treatment in January, the couple dined out as many as six times a month. Today, their visits to chains like McDonald’s and Burger King have dropped by nearly half.
She describes making far more conscious choices: instead of a massive 20-ounce steak at Texas Roadhouse, she now picks a noticeably smaller portion. Her husband, who used to order a full Taco Bell meal with tacos, a soda, and burritos, now struggles to finish even half of that.
The Numbers Are Alarming Wall Street
The impact of GLP-1 drugs is not limited to individual stories. According to a Gallup poll, more than 12% of Americans said they are using this type of medication for weight loss, a figure that has doubled since early 2024.
J.P. Morgan analysts estimate that by 2030, more than 30 million Americans will be on GLP-1 therapies, particularly if pill-form versions receive wide approval and become more widely available.
These figures have already set off alarm bells on Wall Street. Investors and analysts are poring over which companies stand to gain and which stand to lose from the new trend.
A Cornell University study of 150,000 households found that families with at least one GLP-1 user cut their spending at fast food outlets, cafes, and quick-service chains by 8% within just six months of starting treatment.
Businesses that rely on high volumes, fried food, and overconsumption are considered most exposed. By contrast, fast-casual chains with a focus on healthier or more customizable options appear to be benefiting.
How Chains Are Responding: Protein and Smaller Portions
Faced with these changes, American restaurant chains are already adjusting their strategy.
McDonald’s has started highlighting the protein content of its products more prominently, since many GLP-1 users are focused on preserving muscle mass while losing weight.
KFC, meanwhile, is investing in smaller portions and snack-sized options, betting that chicken’s high protein content can attract the new generation of consumers.
Panera Bread went even further, conducting customer research to better understand the needs of GLP-1 users. According to the company’s own data, about 17% of its customers use these drugs, a figure significantly higher than the national average. The chain responded by offering smaller portions, half-sandwich-and-salad combos, and options seen as healthier without sacrificing flavor.
The End of the Supersized Meal?
Even chains long associated with excess are adapting. Olive Garden, famous for its unlimited breadsticks, launched a new lighter-portions menu this year on a national scale. The company acknowledges that the move is partly aimed at GLP-1 users, while noting it also targets consumers broadly looking for more affordable or health-conscious options.
Michelle Ambrosio Chambers from Texas, who has lost about 68 kilograms over three years thanks to GLP-1 drugs, says she now avoids heavy combo meals and opts for customized, calorie-controlled options. She still eats out, she admits, but far less often and definitely not in the quantities of the past.
A Change That’s Here to Stay?
While some experts note that many patients eventually stop treatment and partly revert to old habits, the market broadly believes the changes driven by GLP-1 drugs are already powerful enough to reshape the restaurant industry.
For decades, the American food industry was built on large portions and overconsumption. The new generation of consumers, however, seems to want exactly the opposite: less food, better quality, and greater control over their choices.
And that may well prove to be the biggest shift the industry has seen in years.
